Vasa Therapeutics sp. z o.o.

Research and experimental development on biotechnology

KRS: NIP: REGON:

Overview

Status
Active
Registry date
2019-10-16
Share capital
9,450.00 PLN
Average employment (people)
2 (2025)
Activity description

Vasa Therapeutics develops therapies that target validated mechanisms in cardiovascular, neuromuscular and age-related disorders. Its pipeline includes four assets, including VS-041, a narrow-spectrum MMP-2 and MMP-9 inhibitor for heart failure with preserved ejection fraction, and long-acting apelin analogs for peripheral artery disease, neuromuscular diseases and sarcopenia.

Registered address
ul. Duńska 9/2/23, 54-427 Wrocław, Poland
Email
Phone
Social media
Electronic delivery address
AE:PL-41272-42031-SSVHB-23

Financials

Revenue history (in k)

From the notes

Profit allocationLoss to be covered
Capital expenditure$15,574
Contingent liabilitiesYes
Management board pay$57,132
Parent companyVASA THERAPEUTICS, INC.

Filing timeliness

Financial statements were filed on time, on average 42 days early.

  • 202501/07/2026
  • 202401/07/2025
  • 202303/06/2024
  • 202230/06/2023
  • 202120/05/2022
  • 202028/06/2021
Filed on timeDelayFiling deadline

Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.

Statistics

How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2025.

Top 25%
City · Wrocław5,661 / 13,650
Top 41%
Voivodeship · Dolnośląskie10,811 / 23,831
Top 45%
Country · Poland137,815 / 297,069
Top 46%

Results vs industry

Revenue
This companyUSD 363.11kMedianUSD 56.72kAverageUSD 2.72m
Net profit
This companyUSD -172.47kMedianUSD -1.27kAverageUSD -93.01k
Operating costs
This companyUSD 499.86kMedianUSD 66.48kAverageUSD 2.68m
Assets
This companyUSD 3.35mMedianUSD 134.71kAverageUSD 3.04m

Industry

Offer

  • Cardiology medicines
  • Neuromuscular drugs
  • Anti-aging drugs
  • Therapeutic candidates

Websites

Authorized Representatives

Artur Płonowski age 61 – President of the Management Board
Sławomir Różewicz age 49 – Attorney-in-fact (sole)

Manner of representation

In the case of a one-person management board, that member of the management board makes declarations of will on behalf of the company. In the case of a management board consisting of two or more persons, two members of the management board acting jointly or a member of the management board acting jointly with a commercial proxy are authorised to make declarations of will on behalf of the company.

Ownership

OwnerSharesShare valueStake
Vasa Therapeutics, Inc.
189$2,552.67100%

Beneficial owners

Person

Bank accounts

Registered as a VAT taxpayer on 2020-07-20.

Debt

No entries in the National Debtors Register (KRZ).

Public aid

5 public aid cases recorded, with a total value of $5,532,661.

PurposeGross amount
Aid for research and development projects: industrial research
$2.5M
Aid for research and development projects: experimental development
$449.5K
Aid for SMEs for innovation support
$15,068

European Funds

ProjectEU co-financing
Development of an innovative matrix metalloproteinase (MMP) inhibitor as the first-in-class drug modifying the progression of MMVD and SAS in dogs.
$3.7M
Preclinical work and Phase I clinical trials of an innovative drug candidate for HFpEF heart failure
$2.6M

Regulatory authorisations

AuthorityTypeStatus
BDO register entry Active

Competitors

Change history

DateEvent
2025-12-02Address change
2025-12-02Share capital increase
2024-10-23Share capital increase
2024-07-25Share capital increase
2024-02-22Share capital increase

FAQ

Last updated: 2026-10-07